These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26152085)

  • 21. Malignant melanoma-The cradle of anti-neoplastic immunotherapy.
    Koller KM; Wang W; Schell TD; Cozza EM; Kokolus KM; Neves RI; Mackley HB; Pameijer C; Leung A; Anderson B; Mallon CA; Robertson G; Drabick JJ
    Crit Rev Oncol Hematol; 2016 Oct; 106():25-54. PubMed ID: 27637351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
    Agarwala SS
    Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Normalization Cancer Immunotherapy for Melanoma.
    Vesely MD; Chen L
    J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of advanced or metastatic melanoma.
    Cebon J; Gedye C; John T; Davis ID
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in specific immunotherapy of malignant melanoma.
    Curiel-Lewandrowski C; Demierre MF
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 1):167-85; quiz 186-8. PubMed ID: 10906637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical management of melanoma.
    Brown CK; Kirkwood JM
    Surg Clin North Am; 2003 Apr; 83(2):283-322, viii. PubMed ID: 12744611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges.
    Millet A; Martin AR; Ronco C; Rocchi S; Benhida R
    Med Res Rev; 2017 Jan; 37(1):98-148. PubMed ID: 27569556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy.
    Kottschade L; Brys A; Peikert T; Ryder M; Raffals L; Brewer J; Mosca P; Markovic S;
    Melanoma Res; 2016 Oct; 26(5):469-80. PubMed ID: 27306502
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of malignant melanoma.
    Kadison AS; Morton DL
    Surg Clin North Am; 2003 Apr; 83(2):343-70. PubMed ID: 12744613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [New treatments for metastatic melanoma: a first hope].
    Robert C; Mateus C
    Rev Prat; 2011 Nov; 61(9 Suppl):S1-2. PubMed ID: 22338196
    [No Abstract]   [Full Text] [Related]  

  • 31. T cell receptor therapy against melanoma-Immunotherapy for the future?
    Winge-Main AK; Wälchli S; Inderberg EM
    Scand J Immunol; 2020 Oct; 92(4):e12927. PubMed ID: 32640053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy for Melanoma.
    Albittar AA; Alhalabi O; Glitza Oliva IC
    Adv Exp Med Biol; 2020; 1244():51-68. PubMed ID: 32301010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of immunotherapy in the treatment of melanoma.
    Faries MB
    Surg Oncol Clin N Am; 2006 Apr; 15(2):399-418. PubMed ID: 16632223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The treatment of melanoma with an emphasis on immunotherapeutic strategies.
    Jack A; Boyes C; Aydin N; Alam K; Wallack M
    Surg Oncol; 2006 Jul; 15(1):13-24. PubMed ID: 16815006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging therapies for melanoma.
    Katipamula R; Markovic SN
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):553-60. PubMed ID: 18402522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
    Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
    Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Targets in Melanoma: Intralesional and Combination Therapy to Manipulate the Immune Response.
    Gingrich AA; Kirane AR
    Surg Oncol Clin N Am; 2020 Jul; 29(3):467-483. PubMed ID: 32482321
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
    Eggermont AM; Maio M; Robert C
    Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.